http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 14 Aug 2026 06:06:35 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Hot+New+Coverage/Raymond+James+Starts+SpyGlass+Pharma+%28SGP%29+at+Outperform/26923818.html (Updated - August 14, 2026 6:06 AM EDT) <p>Raymond James analyst Christopher Raymond initiates coverage on SpyGlass Pharma (NASDAQ: SGP) with a Outperform rating and a price target of $39.00.</p><p>The analyst comments "We are initiating coverage of SGP shares with an Outperform rating and $39 price target. At the center of our thesis is BIM-IOL, a proprietary sustained-release (SR) bimatoprost intraocular lens (IOL) designed to treat patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) at the time of routine cataract surgery. SGP is targeting the large overlap between cataract and glaucoma patients at a natural point of intervention, with a http://www.streetinsider.com/Hot+New+Coverage/Raymond+James+Starts+SpyGlass+Pharma+%28SGP%29+at+Outperform/26923818.html Fri, 14 Aug 2026 06:06:35 -0400 SGP http://www.streetinsider.com/New+Coverage/Raymond+James+Starts+SpyGlass+Pharma+%28SGP%29+at+Outperform/26923818.html (Updated - August 14, 2026 6:06 AM EDT) <p>Raymond James analyst Christopher Raymond initiates coverage on SpyGlass Pharma (NASDAQ: SGP) with a Outperform rating and a price target of $39.00.</p><p>The analyst comments "We are initiating coverage of SGP shares with an Outperform rating and $39 price target. At the center of our thesis is BIM-IOL, a proprietary sustained-release (SR) bimatoprost intraocular lens (IOL) designed to treat patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) at the time of routine cataract surgery. SGP is targeting the large overlap between cataract and glaucoma patients at a natural point of intervention, with a http://www.streetinsider.com/New+Coverage/Raymond+James+Starts+SpyGlass+Pharma+%28SGP%29+at+Outperform/26923818.html Fri, 14 Aug 2026 06:06:35 -0400 SGP http://www.streetinsider.com/Analyst+Comments/Raymond+James+Starts+SpyGlass+Pharma+%28SGP%29+at+Outperform/26923818.html (Updated - August 14, 2026 6:06 AM EDT) <p>Raymond James analyst Christopher Raymond initiates coverage on SpyGlass Pharma (NASDAQ: SGP) with a Outperform rating and a price target of $39.00.</p><p>The analyst comments "We are initiating coverage of SGP shares with an Outperform rating and $39 price target. At the center of our thesis is BIM-IOL, a proprietary sustained-release (SR) bimatoprost intraocular lens (IOL) designed to treat patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) at the time of routine cataract surgery. SGP is targeting the large overlap between cataract and glaucoma patients at a natural point of intervention, with a http://www.streetinsider.com/Analyst+Comments/Raymond+James+Starts+SpyGlass+Pharma+%28SGP%29+at+Outperform/26923818.html Fri, 14 Aug 2026 06:06:35 -0400 SGP http://www.streetinsider.com/Hot+Comments/Raymond+James+Starts+SpyGlass+Pharma+%28SGP%29+at+Outperform/26923818.html (Updated - August 14, 2026 6:06 AM EDT) <p>Raymond James analyst Christopher Raymond initiates coverage on SpyGlass Pharma (NASDAQ: SGP) with a Outperform rating and a price target of $39.00.</p><p>The analyst comments "We are initiating coverage of SGP shares with an Outperform rating and $39 price target. At the center of our thesis is BIM-IOL, a proprietary sustained-release (SR) bimatoprost intraocular lens (IOL) designed to treat patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) at the time of routine cataract surgery. SGP is targeting the large overlap between cataract and glaucoma patients at a natural point of intervention, with a http://www.streetinsider.com/Hot+Comments/Raymond+James+Starts+SpyGlass+Pharma+%28SGP%29+at+Outperform/26923818.html Fri, 14 Aug 2026 06:06:35 -0400 SGP http://www.streetinsider.com/Earnings/SpyGlass+Pharma+%28SGP%29+Reports+Q2+Loss+of+%240.59/26891212.html <p>SpyGlass Pharma (NASDAQ: SGP) reported Q2 EPS of ($0.59).</p><p>For earnings history and earnings-related data on SpyGlass Pharma (SGP) <a href="http://www.streetinsider.com/ec_earnings.php?q=SGP">click here</a>.</p> http://www.streetinsider.com/Earnings/SpyGlass+Pharma+%28SGP%29+Reports+Q2+Loss+of+%240.59/26891212.html Fri, 07 Aug 2026 16:15:16 -0400 SGP http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++SpyGlass+Pharma%2C+Inc.+++++For%3A+Jun+30/26884930.html si-local-file:///var/storage/secattach/20260806/26884930.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++SpyGlass+Pharma%2C+Inc.+++++For%3A+Jun+30/26884930.html Thu, 06 Aug 2026 16:37:00 -0400 O.76922640 SGP http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++SpyGlass+Pharma%2C+Inc.+++++For%3A+Jun+30/26884930.html si-local-file:///var/storage/secattach/20260806/26884930.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++SpyGlass+Pharma%2C+Inc.+++++For%3A+Jun+30/26884930.html Thu, 06 Aug 2026 16:37:00 -0400 O.76922640 SGP http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SpyGlass+Pharma%2C+Inc.+++++For%3A+Aug+06/26884284.html si-local-file:///var/storage/secattach/20260806/26884284.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SpyGlass+Pharma%2C+Inc.+++++For%3A+Aug+06/26884284.html Thu, 06 Aug 2026 16:17:00 -0400 O.76922640 SGP http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SpyGlass+Pharma%2C+Inc.+++++For%3A+Aug+06/26884284.html si-local-file:///var/storage/secattach/20260806/26884284.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SpyGlass+Pharma%2C+Inc.+++++For%3A+Aug+06/26884284.html Thu, 06 Aug 2026 16:17:00 -0400 O.76922640 SGP http://www.streetinsider.com/Press+Releases/SpyGlass+Pharma+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26883622.html <ul type="disc"><li>Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), with completion of enrollment expected in 2027.<br/></li><li>Bimatoprost-Drug Ring System (BIM-DRS) first-in-human trial is on track to start in the second half of 2026.<br/></li><li>Cash, cash equivalents and short-term investments of $234.2 million on June 30, 2026, are expected to fund planned operations through 2028.<br/><br/></li></ul> <p>IRVINE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today reported recent business highlights and financial results for the second quarter ended June http://www.streetinsider.com/Press+Releases/SpyGlass+Pharma+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26883622.html Thu, 06 Aug 2026 16:05:00 -0400 A.06822034 O.20026344 O.76922640 SGP http://www.streetinsider.com/Press+Releases/SpyGlass+Pharma+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26883622.html <ul type="disc"><li>Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), with completion of enrollment expected in 2027.<br/></li><li>Bimatoprost-Drug Ring System (BIM-DRS) first-in-human trial is on track to start in the second half of 2026.<br/></li><li>Cash, cash equivalents and short-term investments of $234.2 million on June 30, 2026, are expected to fund planned operations through 2028.<br/><br/></li></ul> <p>IRVINE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today reported recent business highlights and financial results for the second quarter ended June http://www.streetinsider.com/Press+Releases/SpyGlass+Pharma+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26883622.html Thu, 06 Aug 2026 16:05:00 -0400 A.06822034 O.20026344 O.76922640 SGP http://www.streetinsider.com/Press+Releases/SpyGlass+Pharma+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26883622.html <ul type="disc"><li>Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), with completion of enrollment expected in 2027.<br/></li><li>Bimatoprost-Drug Ring System (BIM-DRS) first-in-human trial is on track to start in the second half of 2026.<br/></li><li>Cash, cash equivalents and short-term investments of $234.2 million on June 30, 2026, are expected to fund planned operations through 2028.<br/><br/></li></ul> <p>IRVINE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today reported recent business highlights and financial results for the second quarter ended June http://www.streetinsider.com/Press+Releases/SpyGlass+Pharma+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26883622.html Thu, 06 Aug 2026 16:05:00 -0400 A.06822034 O.20026344 O.76922640 SGP http://www.streetinsider.com/Press+Releases/SpyGlass+Pharma+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26883622.html <ul type="disc"><li>Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), with completion of enrollment expected in 2027.<br/></li><li>Bimatoprost-Drug Ring System (BIM-DRS) first-in-human trial is on track to start in the second half of 2026.<br/></li><li>Cash, cash equivalents and short-term investments of $234.2 million on June 30, 2026, are expected to fund planned operations through 2028.<br/><br/></li></ul> <p>IRVINE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today reported recent business highlights and financial results for the second quarter ended June http://www.streetinsider.com/Press+Releases/SpyGlass+Pharma+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26883622.html Thu, 06 Aug 2026 16:05:00 -0400 A.06822034 O.20026344 O.76922640 SGP http://www.streetinsider.com/Globe+Newswire/SpyGlass+Pharma+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26883622.html <ul type="disc"><li>Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), with completion of enrollment expected in 2027.<br/></li><li>Bimatoprost-Drug Ring System (BIM-DRS) first-in-human trial is on track to start in the second half of 2026.<br/></li><li>Cash, cash equivalents and short-term investments of $234.2 million on June 30, 2026, are expected to fund planned operations through 2028.<br/><br/></li></ul> <p>IRVINE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today reported recent business highlights and financial results for the second quarter ended June http://www.streetinsider.com/Globe+Newswire/SpyGlass+Pharma+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26883622.html Thu, 06 Aug 2026 16:05:00 -0400 A.06822034 O.20026344 O.76922640 SGP http://www.streetinsider.com/Globe+Newswire/SpyGlass+Pharma+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26883622.html <ul type="disc"><li>Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), with completion of enrollment expected in 2027.<br/></li><li>Bimatoprost-Drug Ring System (BIM-DRS) first-in-human trial is on track to start in the second half of 2026.<br/></li><li>Cash, cash equivalents and short-term investments of $234.2 million on June 30, 2026, are expected to fund planned operations through 2028.<br/><br/></li></ul> <p>IRVINE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today reported recent business highlights and financial results for the second quarter ended June http://www.streetinsider.com/Globe+Newswire/SpyGlass+Pharma+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26883622.html Thu, 06 Aug 2026 16:05:00 -0400 A.06822034 O.20026344 O.76922640 SGP http://www.streetinsider.com/Globe+Newswire/SpyGlass+Pharma+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26883622.html <ul type="disc"><li>Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), with completion of enrollment expected in 2027.<br/></li><li>Bimatoprost-Drug Ring System (BIM-DRS) first-in-human trial is on track to start in the second half of 2026.<br/></li><li>Cash, cash equivalents and short-term investments of $234.2 million on June 30, 2026, are expected to fund planned operations through 2028.<br/><br/></li></ul> <p>IRVINE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today reported recent business highlights and financial results for the second quarter ended June http://www.streetinsider.com/Globe+Newswire/SpyGlass+Pharma+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26883622.html Thu, 06 Aug 2026 16:05:00 -0400 A.06822034 O.20026344 O.76922640 SGP http://www.streetinsider.com/Globe+Newswire/SpyGlass+Pharma+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26883622.html <ul type="disc"><li>Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), with completion of enrollment expected in 2027.<br/></li><li>Bimatoprost-Drug Ring System (BIM-DRS) first-in-human trial is on track to start in the second half of 2026.<br/></li><li>Cash, cash equivalents and short-term investments of $234.2 million on June 30, 2026, are expected to fund planned operations through 2028.<br/><br/></li></ul> <p>IRVINE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today reported recent business highlights and financial results for the second quarter ended June http://www.streetinsider.com/Globe+Newswire/SpyGlass+Pharma+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26883622.html Thu, 06 Aug 2026 16:05:00 -0400 A.06822034 O.20026344 O.76922640 SGP http://www.streetinsider.com/Management+Changes/SpyGlass+Pharma+names+Shannon+Trevi%C3%B1o+as+general+counsel/26644492.html <p>SpyGlass Pharma Inc. (NASDAQ: SGP) appointed Shannon Treviño as general counsel, the biopharmaceutical company announced June 15.</p><p>Treviño previously served as general counsel and corporate secretary at Inari Medical, where she oversaw legal and compliance functions during the company's $4.9 billion acquisition by Stryker. She also managed Inari's acquisition of LimFlow and its integration.</p><p>Before joining Inari, Treviño worked as an attorney at Sugg Law Group, advising early and growth-stage companies on governance, commercial contracts, capital formation and mergers and acquisitions. She spent eight years as a clinical professor and director of the Transactional Lawyering Institute at Loyola Marymount University's Law School, http://www.streetinsider.com/Management+Changes/SpyGlass+Pharma+names+Shannon+Trevi%C3%B1o+as+general+counsel/26644492.html Mon, 15 Jun 2026 08:02:06 -0400 SGP http://www.streetinsider.com/Press+Releases/SpyGlass+Pharma+Appoints+Shannon+Trevi%C3%B1o+as+General+Counsel/26644419.html <p>ALISO VIEJO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma or Company), a late-stage biopharmaceutical company, today announced the appointment of Shannon Treviño as general counsel. Ms. Treviño brings significant business-oriented legal experience and leadership that results in operating excellence for publicly traded companies at various stages of growth.</p> <p>“We are delighted to welcome Shannon to our growing team. She is a proven leader with a track record of guiding complex organizations through periods of growth,” said Patrick Mooney, CEO of SpyGlass Pharma. “The team we are building at SpyGlass is http://www.streetinsider.com/Press+Releases/SpyGlass+Pharma+Appoints+Shannon+Trevi%C3%B1o+as+General+Counsel/26644419.html Mon, 15 Jun 2026 08:00:00 -0400 A.06822034 A.09399774 A.50114142 O.00048820 O.20026344 O.47578892 SGP http://www.streetinsider.com/Press+Releases/SpyGlass+Pharma+Appoints+Shannon+Trevi%C3%B1o+as+General+Counsel/26644419.html <p>ALISO VIEJO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma or Company), a late-stage biopharmaceutical company, today announced the appointment of Shannon Treviño as general counsel. Ms. Treviño brings significant business-oriented legal experience and leadership that results in operating excellence for publicly traded companies at various stages of growth.</p> <p>“We are delighted to welcome Shannon to our growing team. She is a proven leader with a track record of guiding complex organizations through periods of growth,” said Patrick Mooney, CEO of SpyGlass Pharma. “The team we are building at SpyGlass is http://www.streetinsider.com/Press+Releases/SpyGlass+Pharma+Appoints+Shannon+Trevi%C3%B1o+as+General+Counsel/26644419.html Mon, 15 Jun 2026 08:00:00 -0400 A.06822034 A.09399774 A.50114142 O.00048820 O.20026344 O.47578892 SGP http://www.streetinsider.com/Press+Releases/SpyGlass+Pharma+Appoints+Shannon+Trevi%C3%B1o+as+General+Counsel/26644419.html <p>ALISO VIEJO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma or Company), a late-stage biopharmaceutical company, today announced the appointment of Shannon Treviño as general counsel. Ms. Treviño brings significant business-oriented legal experience and leadership that results in operating excellence for publicly traded companies at various stages of growth.</p> <p>“We are delighted to welcome Shannon to our growing team. She is a proven leader with a track record of guiding complex organizations through periods of growth,” said Patrick Mooney, CEO of SpyGlass Pharma. “The team we are building at SpyGlass is http://www.streetinsider.com/Press+Releases/SpyGlass+Pharma+Appoints+Shannon+Trevi%C3%B1o+as+General+Counsel/26644419.html Mon, 15 Jun 2026 08:00:00 -0400 A.06822034 A.09399774 A.50114142 O.00048820 O.20026344 O.47578892 SGP http://www.streetinsider.com/Press+Releases/SpyGlass+Pharma+Appoints+Shannon+Trevi%C3%B1o+as+General+Counsel/26644419.html <p>ALISO VIEJO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma or Company), a late-stage biopharmaceutical company, today announced the appointment of Shannon Treviño as general counsel. Ms. Treviño brings significant business-oriented legal experience and leadership that results in operating excellence for publicly traded companies at various stages of growth.</p> <p>“We are delighted to welcome Shannon to our growing team. She is a proven leader with a track record of guiding complex organizations through periods of growth,” said Patrick Mooney, CEO of SpyGlass Pharma. “The team we are building at SpyGlass is http://www.streetinsider.com/Press+Releases/SpyGlass+Pharma+Appoints+Shannon+Trevi%C3%B1o+as+General+Counsel/26644419.html Mon, 15 Jun 2026 08:00:00 -0400 A.06822034 A.09399774 A.50114142 O.00048820 O.20026344 O.47578892 SGP http://www.streetinsider.com/Press+Releases/SpyGlass+Pharma+Appoints+Shannon+Trevi%C3%B1o+as+General+Counsel/26644419.html <p>ALISO VIEJO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma or Company), a late-stage biopharmaceutical company, today announced the appointment of Shannon Treviño as general counsel. Ms. Treviño brings significant business-oriented legal experience and leadership that results in operating excellence for publicly traded companies at various stages of growth.</p> <p>“We are delighted to welcome Shannon to our growing team. She is a proven leader with a track record of guiding complex organizations through periods of growth,” said Patrick Mooney, CEO of SpyGlass Pharma. “The team we are building at SpyGlass is http://www.streetinsider.com/Press+Releases/SpyGlass+Pharma+Appoints+Shannon+Trevi%C3%B1o+as+General+Counsel/26644419.html Mon, 15 Jun 2026 08:00:00 -0400 A.06822034 A.09399774 A.50114142 O.00048820 O.20026344 O.47578892 SGP http://www.streetinsider.com/Press+Releases/SpyGlass+Pharma+Appoints+Shannon+Trevi%C3%B1o+as+General+Counsel/26644419.html <p>ALISO VIEJO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma or Company), a late-stage biopharmaceutical company, today announced the appointment of Shannon Treviño as general counsel. Ms. Treviño brings significant business-oriented legal experience and leadership that results in operating excellence for publicly traded companies at various stages of growth.</p> <p>“We are delighted to welcome Shannon to our growing team. She is a proven leader with a track record of guiding complex organizations through periods of growth,” said Patrick Mooney, CEO of SpyGlass Pharma. “The team we are building at SpyGlass is http://www.streetinsider.com/Press+Releases/SpyGlass+Pharma+Appoints+Shannon+Trevi%C3%B1o+as+General+Counsel/26644419.html Mon, 15 Jun 2026 08:00:00 -0400 A.06822034 A.09399774 A.50114142 O.00048820 O.20026344 O.47578892 SGP http://www.streetinsider.com/Press+Releases/SpyGlass+Pharma+Appoints+Shannon+Trevi%C3%B1o+as+General+Counsel/26644419.html <p>ALISO VIEJO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma or Company), a late-stage biopharmaceutical company, today announced the appointment of Shannon Treviño as general counsel. Ms. Treviño brings significant business-oriented legal experience and leadership that results in operating excellence for publicly traded companies at various stages of growth.</p> <p>“We are delighted to welcome Shannon to our growing team. She is a proven leader with a track record of guiding complex organizations through periods of growth,” said Patrick Mooney, CEO of SpyGlass Pharma. “The team we are building at SpyGlass is http://www.streetinsider.com/Press+Releases/SpyGlass+Pharma+Appoints+Shannon+Trevi%C3%B1o+as+General+Counsel/26644419.html Mon, 15 Jun 2026 08:00:00 -0400 A.06822034 A.09399774 A.50114142 O.00048820 O.20026344 O.47578892 SGP